Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,023,932 papers from all fields of science
Search
Sign In
Create Free Account
Johnson and Johnson
Known as:
Johnson & Johnson
health product manufacturer
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh
,
L. Gensler
,
+6 authors
B. Strober
Drug Safety
2019
Corpus ID: 73435213
IntroductionTheoretical risks of biologic agents remain under study.ObjectiveThe aim of this study was to integrate 1-year safety…
Expand
Review
2014
Review
2014
External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR).
C. Mahan
,
Yang Liu
,
+5 authors
A. Spyropoulos
Thrombosis and Haemostasis
2014
Corpus ID: 24839575
Venous thromboembolic (VTE) risk assessment remains an important issue in hospitalised, acutely-ill medical patients, and several…
Expand
2014
2014
STARR with CONTOUR® TRANSTAR™ device for obstructed defecation syndrome: one-year real-world outcomes of the European TRANSTAR registry
G. Ribaric
,
A. D'hoore
,
G. Schiffhorst
,
E. Hempel
International Journal of Colorectal Disease
2014
Corpus ID: 18600723
PurposeStapled transanal rectal resection (STARR) in patients with obstructive defecation syndrome (ODS) is limited by the…
Expand
2013
2013
First novel anti-tuberculosis drug in 40 years
R. Osborne
Nature Biotechnology
2013
Corpus ID: 20639439
89 opment organization, established in 2000 to boost research into TB drugs. Sirturo, unlike other antibiotics that attack the…
Expand
Highly Cited
2012
Highly Cited
2012
Sting of Alzheimer's failures offset by upcoming prevention trials
Asher Mullard
Nature reviews. Drug discovery
2012
Corpus ID: 1980413
Three prevention trials in asymptomatic Alzheimer's disease patients will attempt to validate the amyloid hypothesis, evaluate…
Expand
Review
2010
Review
2010
How Informatics Can Potentiate Precompetitive Open‐Source Collaboration to Jump‐Start Drug Discovery and Development
E. Perakslis
,
J. Dam
,
S. Szalma
Clinical pharmacology and therapy
2010
Corpus ID: 3274633
Much enthusiasm and energy are being directed toward open‐source software approaches, precompetitive data sharing, and external…
Expand
Highly Cited
2009
Highly Cited
2009
Numerical and Clinical Accuracy of a Continuous Glucose Monitoring System during Intravenous Insulin Therapy in the Surgical and Burn Intensive Care Units
A. Rabiee
,
Virginia Andreasik
,
+5 authors
D. Elahi
Journal of Diabetes Science and Technology
2009
Corpus ID: 44756832
Background: Intensive insulin therapy (IIT) for glycemic control in critically ill patients has been shown to be beneficial…
Expand
Highly Cited
2008
Highly Cited
2008
The Bacteria Fight Back
G. Taubes
Science
2008
Corpus ID: 45327957
In their ongoing war against antibiotics, the bacteria seem to be winning, and the drug pipeline is verging on empty.
2008
2008
Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study
R. Ganguli
,
J. Brar
,
R. Mahmoud
,
S. Berry
,
G. Pandina
BMC Medicine
2008
Corpus ID: 13038908
BackgroundIn clinical practice, physicians often need to change the antipsychotic medications they give to patients because of an…
Expand
2005
2005
An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening.
J. van Gompel
,
F. Woestenborghs
,
+6 authors
R. Walmsley
Mutagenesis
2005
Corpus ID: 18057866
In this paper we describe an initial reproducibility study of 12 proprietary compounds followed by the assessment of 51 marketed…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE